259 related articles for article (PubMed ID: 34617445)
21. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
Cohn EF; Zhuo J; Kelly ME; Chao HJ
J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
[TBL] [Abstract][Full Text] [Related]
22. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM
Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925
[TBL] [Abstract][Full Text] [Related]
23. Enhancing transduction of the liver by adeno-associated viral vectors.
Nathwani AC; Cochrane M; McIntosh J; Ng CY; Zhou J; Gray JT; Davidoff AM
Gene Ther; 2009 Jan; 16(1):60-9. PubMed ID: 18701909
[TBL] [Abstract][Full Text] [Related]
24. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.
Jiang H; Pierce GF; Ozelo MC; de Paula EV; Vargas JA; Smith P; Sommer J; Luk A; Manno CS; High KA; Arruda VR
Mol Ther; 2006 Sep; 14(3):452-5. PubMed ID: 16822719
[TBL] [Abstract][Full Text] [Related]
25. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.
Brown HC; Doering CB; Herzog RW; Ling C; Markusic DM; Spencer HT; Srivastava A; Srivastava A
Hum Gene Ther; 2020 Oct; 31(19-20):1114-1123. PubMed ID: 32657150
[TBL] [Abstract][Full Text] [Related]
26. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.
Cooper M; Nayak S; Hoffman BE; Terhorst C; Cao O; Herzog RW
Hum Gene Ther; 2009 Jul; 20(7):767-76. PubMed ID: 19309290
[TBL] [Abstract][Full Text] [Related]
27. What´s new in Gene Therapy of Hemophilia.
Rodriguez-Merchan EC
Curr Gene Ther; 2018; 18(2):107-114. PubMed ID: 29446741
[TBL] [Abstract][Full Text] [Related]
28. Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice.
Le Quellec S; Dane AP; Barbon E; Bordet JC; Mingozzi F; Dargaud Y; Marais T; Biferi MG; Négrier C; Nathawani AC; Enjolras N
Thromb Haemost; 2019 Dec; 119(12):1956-1967. PubMed ID: 31659733
[TBL] [Abstract][Full Text] [Related]
29. Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.
Shao W; Earley LF; Chai Z; Chen X; Sun J; He T; Deng M; Hirsch ML; Ting J; Samulski RJ; Li C
JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925692
[TBL] [Abstract][Full Text] [Related]
30. Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs.
Nichols TC; Whitford MH; Arruda VR; Stedman HH; Kay MA; High KA
Hum Gene Ther Clin Dev; 2015 Mar; 26(1):5-14. PubMed ID: 25675273
[TBL] [Abstract][Full Text] [Related]
31. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
[TBL] [Abstract][Full Text] [Related]
32. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
[TBL] [Abstract][Full Text] [Related]
33. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR
Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027
[TBL] [Abstract][Full Text] [Related]
35. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
Hasbrouck NC; High KA
Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
[TBL] [Abstract][Full Text] [Related]
36. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA
Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752
[TBL] [Abstract][Full Text] [Related]
37. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.
Jiang H; Couto LB; Patarroyo-White S; Liu T; Nagy D; Vargas JA; Zhou S; Scallan CD; Sommer J; Vijay S; Mingozzi F; High KA; Pierce GF
Blood; 2006 Nov; 108(10):3321-8. PubMed ID: 16868252
[TBL] [Abstract][Full Text] [Related]
38. Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration.
Chai Z; Zhang X; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2018 Sep; 286():415-424. PubMed ID: 30107215
[TBL] [Abstract][Full Text] [Related]
39. AAV-mediated gene transfer for hemophilia.
High KA
Ann N Y Acad Sci; 2001 Dec; 953():64-74. PubMed ID: 11795424
[TBL] [Abstract][Full Text] [Related]
40. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors.
Chao H; Liu Y; Rabinowitz J; Li C; Samulski RJ; Walsh CE
Mol Ther; 2000 Dec; 2(6):619-23. PubMed ID: 11124063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
